Profusa Scales Back IPO Plans, Opts for Smaller Funding Round

Event summary

  • Profusa withdraws its S-1 registration statement filed on February 13, 2026, for a $15 million offering.
  • Company plans a smaller, more focused offering to support near-term revenue from Europe LumeeTM Oxygen product launches in Q2 2026.
  • Profusa aims to invest in its Mayo Clinic collaboration for U.S. market entry and new product development.
  • No securities were sold in connection with the withdrawn offering.

The big picture

Profusa's decision to withdraw its IPO and pursue a smaller funding round reflects a strategic pivot to align with its near-term revenue projections and operational needs. The move highlights the company's focus on scaling its Lumee Oxygen product in Europe and the U.S., leveraging its collaboration with Mayo Clinic. This shift comes amid broader trends in the digital health sector, where companies are increasingly prioritizing targeted, phased market entries to optimize capital efficiency and operational agility.

What we're watching

Revenue Execution
Whether Profusa can meet its projected revenue targets from the Europe Lumee Oxygen product launches in Q2 2026.
Market Timing
The pace at which Profusa can secure a smaller funding round and accelerate its U.S. market entry with Mayo Clinic.
Product Development
How Profusa's investment in new continuous oxygen monitoring products will impact its long-term competitive positioning.